On 8 November 2023, Tirzepatide, branded as Zepbound in the US, received FDA approval as the first dual-target agonist for the treatment of obesity, further highlighting its potential in medical treatment options
Esta hormona se libera de forma natural tras las comidas y ayuda a regular el azcar en sangre, la saciedad y el vaciamiento gstrico
While several peptides promise to take your bedroom game to the next level, one particular prescription peptide, PT-141, is the breakout star
This research offers further insight into this emerging safety signal, according to the study authors who noted in their Ophthalmology paper, Our novel, stratified analysis provides a more nuanced interpretation than previous pooled reviews, isolating a potential increased risk signal to observational data in the diabetes population only, a finding not corroborated by RCTs. These results are somewhat at odds with the narrative surrounding GLP-1 use and NAION risk that began in early 2024, but the researchers say they are confident in their methodology
